Peter H. St George-Hyslop
Founder at Transition Bio, Inc.
Peter H. St George-Hyslop active positions
| Companies | Position | Start | End |
|---|---|---|---|
Ellipsis Neurotherapeutics, Inc.
 Ellipsis Neurotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ellipsis Neurotherapeutics, Inc. develops pharmaceutical products for treatment and preventing of Alzheimer's disease and related disorders. The firm commercializes neurodegenerative disease therapeutics and diagnostics. The company was founded by Laurence Rubin in November 2004 and is headquartered in Toronto, Canada. | Chief Tech/Sci/R&D Officer | - | - |
Transition Bio, Inc.
 Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles. | Founder | - | - |
Career history of Peter H. St George-Hyslop
Training of Peter H. St George-Hyslop
| University of Ottawa | Undergraduate Degree |
Statistics
International
| Canada | 3 |
| United States | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
| Founder | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Ellipsis Neurotherapeutics, Inc.
Ellipsis Neurotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ellipsis Neurotherapeutics, Inc. develops pharmaceutical products for treatment and preventing of Alzheimer's disease and related disorders. The firm commercializes neurodegenerative disease therapeutics and diagnostics. The company was founded by Laurence Rubin in November 2004 and is headquartered in Toronto, Canada. | Health Technology |
Transition Bio, Inc.
Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles. | Health Technology |
